echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The first GKA new drug disrupts the 30 billion diabetes market! Hengrui, Cinda, Haisco... NDA, star new drug inventory under research!

    The first GKA new drug disrupts the 30 billion diabetes market! Hengrui, Cinda, Haisco... NDA, star new drug inventory under research!

    • Last Update: 2022-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    China is a "diabetic country", with more than 140 million people with diabetes, of which about 72.
    83 million diabetics have not been diagnosed, and because diabetes requires lifelong medication, the therapeutic drug market is sitting on a huge demand
    .
    According to the Pharmarong Cloud database, the sales of diabetes chemicals/biopharmaceuticals in China increased from 20 billion yuan in 2014 to 34.
    3 billion yuan in 2021, with a compound annual growth rate of 7.
    99%.

    Hospital sales of diabetes medication

    Screenshot database

    01 30 billion diabetes drug market, the head effect is obvious

    Diabetes mellitus is a metabolic disease characterized by hyperglycemia, and the etiology and pathogenesis are not fully understood
    .
    Its therapeutic drugs can be divided into two categories: non-insulin hypoglycemic drugs and insulin hypoglycemic drugs, and there can be ten categories
    such as biguanides, insulin and its analogues, GLP-1 receptor agonists, sulfonylureas, glitinides, and GKA drugs.
    The Frost & Sullivan report shows that China's current anti-diabetic drug market is mainly occupied by traditional drugs, and basically half of it is occupied
    by insulin.

    According to the statistics of the drug Rongyun database, among the top 10 varieties of diabetes drugs (chemical drugs/biological drugs) in hospital sales in 2021, except for dapagliflozin tablets, sitagliptin phosphate tablets and liraglutide injection, the remaining 7 are insulin and its analogues
    .
    Insulin aspart 30 injection and insulin glargine injection topped the list with sales of more than 3 billion yuan
    .

    Dapagliflozin tablets sitagliptin phosphate tablets liraglutide injection insulin aspart 30 injection insulin glargine injection

    Diabetes medication (chemical/biological) in 2021

    Top 10 varieties in hospital sales

    Data source: Yaorong Cloud National Hospital Sales Database

    02 New drugs to be launched in 2022 are remarkable

    Compared with Hengrui's Henggliflozin, Microchip's siglita, Tanabe Mitsubishi Pharmaceutical's ticogliptin and other new drugs have been approved in China in 2021, there are fewer new drugs approved this year, but they are all remarkable and very eye-catching
    .

    Hua Medicine Pharmaceutical: Dopagliatin tablets

    Hua Medicine Pharmaceutical: Dopagliatin tablets

    On October 8, Hua Medicine Pharmaceutical's first in class hypoglycemic drug dorzagliatin was officially approved by the NMPA for marketing, trade name: Hua Tangning
    .
    Two indications for Huatangning ® were approved at one time, namely: monotherapy for the treatment of untreated type 2 diabetes mellitus and the combination with metformin alone for the treatment of adult patients with
    type 2 diabetes mellitus when metformin alone has poor glycemic control.

    This is the world's first approved glucokinase activator (GKA, Glucokinase Activator), the first innovative drug with a new mechanism in the field of diabetes in the past decade, and the first time to launch the world's first innovative drug
    for type 2 diabetes in China.
    As a GKA drug, dopagliatin reshapes the body's blood glucose homeostasis by repairing the function of glucose kinase (GK) of blood glucose sensor in patients with type 2 diabetes mellitus to achieve the purpose of
    treating type 2 diabetes.

    Eli Lilly: Tirzepatide

    Eli Lilly: Tirzepatide

    In May 2022, the FDA approved Eli Lilly's glucose-dependent insulin-stimulating polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist tirzepatide (trade name: Mounjaro
    ).
    The drug is the first dual-targeted GLP-1R hypoglycemic drug for the treatment of type 2 diabetes, injected only once a week to supplement diet and exercise to improve glycemic control
    in adults with type 2 diabetes.

    Current status of Tirzepatide research and development

    Screenshot source: Yaorong Cloud Global Drug R&D Database

    In China, Lilly first submitted an IND application for tilbotide injection in April 2019, and started clinical trials in August of the same year, and has so far carried out a number of phase III clinical trials for type 2 diabetes, heart failure, and obesity; In September this year, it was declared listed
    in China.

    Click to view clinical trial details

    Screenshot source: Yaorong Cloud China Clinical Trial Database

    03 Involution intensified, waiting for the listing of star new drugs

    Under the normalization of volume procurement and the consistency evaluation policy of generic drugs, the competition in the domestic diabetes generic drug market is gradually entering a fever pitch, and at the same time, it is also forcing domestic companies to move from generic drugs to Fast-follow and First-in-class
    .
    Pharmaceutical companies have accelerated their research and development, and many pharmaceutical companies have gathered hot targets and competed for involvement, and a number of new drugs have entered the phase III clinical stage, and some products have submitted marketing applications
    in China.

    New drugs newly declared for marketing in China

    New drugs newly declared for marketing in China

    In addition to the tilbotide mentioned above, there are currently the following diabetes innovative drugs that have submitted marketing applications that deserve attention
    .

    Sihuan Pharmaceutical: plus agliflozin tablets

    Sihuan Pharmaceutical: plus agliflozin tablets

    On February 28, Sihuan Pharmaceutical's new drug plus agliflozin tablets was accepted
    by CDE.
    This is a glucose-sodium co-transporter 2 (SGLT-2) inhibitor independently developed by Sihuan Pharmaceutical for the treatment of diabetes, which has obtained patents in China, the United States, Europe, Japan and South Korea for the treatment of type 2 diabetes
    .
    If it can be approved for marketing, it will become the second SGLT-2 inhibitor drug
    independently developed in China after Hengrui Proline Hengliflozin Tablets.

    Novo Nordisk: semeglutide tablets

    Novo Nordisk: semeglutide tablets

    On May 27, Novo Nordisk's semegluglutide tablet marketing application was accepted
    by CDE.
    Semeglutide is a GLP-1 receptor agonist, its injection has been approved for marketing in China, tablets have been approved overseas for blood sugar control in adult patients with type 2 diabetes, and is the world's first oral GLP-1 receptor agonist drug (GLP-1RA).

    According to the drug Rongyun database, two phase III clinical trials of semeglutide tablets versus placebo or sitagliptin in patients with type 2 diabetes have been completed, and it is speculated that the indicated indication is the treatment of type 2 diabetes
    .

    Clinical trials carried out in China with semeglutide tablets

    Screenshot source: Yaorong Cloud China Clinical Trial Database

    Hengrui: repagliptin phosphate tablets

    Hengrui: repagliptin phosphate tablets

    Hengrui's repagliptin phosphate tablets, a DPP-4 inhibitor with a structure similar to the already marketed sitagliptin, is also suitable for type 2 diabetes, and was submitted for marketing in September 2020 and accepted
    .
    Proline Henggliflozin tablets reported at the same time were approved for marketing on the first day at the end of 2021, becoming the first self-developed SGLT-2 diabetes drug in China, and whether repagliptin can be approved before the end of 2022 is of concern
    .

    New drugs under development

    New drugs under development

    Novo Nordisk: Icodec

    Novo Nordisk: Icodec

    In addition, no weekly insulin preparation product has been approved for marketing in the world, and Novo Nordisk's Icodec insulin is leading
    the way.
    On October 3, Novo Nordisk announced the positive results of Icodec's Phase IIIa ONWARDS 5 study, and Novo Nordisk also said it expects to apply for regulatory approval
    for Icodec in the United States, the European Union and China in the first half of 2023.

    Innovent Biologics: Mazdutide (IBI362)

    Innovent Biologics: Mazdutide (IBI362)

    GLP-1 receptor agonists have grown rapidly in recent years and have become the non-insulin diabetes drugs with the highest global market share, with dulaglutide, somaglutide, liraglutide, etc.
    being among the leaders
    .
    GLP-1R multi-target agonists have also become a hot competitive direction
    .

    Among them, Mazdutide (IBI362), jointly promoted by Innovent and Eli Lilly, is eye-catching
    .
    This is a GLP-1R/GCGR dual-target agonist whose research on type 2 diabetes has reached the phase II clinical stage
    .
    On July 19, Innovent announced that a multicenter, randomized, placebo/dulaglutide-controlled phase II clinical study of IBI362 in Chinese patients with type 2 diabetes has reached the primary endpoint, with significant hypoglycemic and weight-reducing effects, which can bring comprehensive benefits
    to patients.
    On October 4, Innovent announced a phase III clinical trial
    of IBI362 for overweight or obesity.

    Innovent Biologics Lilly

    Multiple clinical phase III DPP-4 inhibitors

    Multiple clinical phase III DPP-4 inhibitors

    There are many domestic developers of DPP-4 inhibitors, among which the DBPR108 of CSPC Group, the compound tagliptin of Salubris, the selgliptin of Shengshitai, HSK7653 of Haisco and the yodagliptin of Yuandong Biologics have made rapid progress and have reached the phase III clinical stage
    .
    CP Tianqing Nanjing Shunxin has laid out two models, TQ-F3083 and TQ05510, adding full horsepower, and the former is already in the phase II clinical stage
    .

    CSPC Group DBPR108 Salubris Compound Gliptin Shengshitai Sheng Gliptin Haixi HSK7653 Yuandong Bio Yodagliptin Zhengda Tianqing Nanjing Shunxin TQ-F3083TQ05510

    The same DPP-4 inhibitor, different varieties are also different
    .
    At present, DPP-4 inhibitors are mostly taken once a day, of which HSK7653 of Haisco Pharma is taken orally every 2 weeks, and Yoldagliptin of Yuandong Biologics and Bogliptin of Baiji Long Pharmaceutical need to be taken once a
    week.

    Haisco Pharmaceutical HSK7653 Yuandong Bio euagliptin Baiji Long Pharmaceutical Bologliptin

    Eastern Sunshine Medicine: Jungagliflozin

    Eastern Sunshine Medicine: Jungagliflozin

    SGLT-2 targets are one of the hot targets in the field of hypoglycemic drugs in recent years, and SGLT-2 inhibitors increase glucose excretion and reduce blood sugar levels
    by blocking and reducing the reabsorption of glucose by the kidneys, thereby excreting excess glucose through urination.

    Among the SGLT-2 inhibitor drugs currently under development, East Sunshine's Jungagliflozin has made the fastest progress and has reached the clinical phase III
    .
    stage.
    Tadagliflozin from Tianjin Institute of Materia Medica, vanagliflozin from Fosun Pharma and elagliflozin from Shanghai Ellis have also entered clinical trials
    .

    East Sunshine Jungpagliflozin Tianjin Institute of Materia Medica, Tadagliflozin Fosun Pharma Vanagliflozin Shanghai Ellis Elegliflozin

    Both insulin and non-insulin drugs are looking forward to early availability and providing more choices
    for diabetic patients.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.